Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection

Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection

El-Khoury et al., Cancers, 2020 

 

Lung cancer is the deadliest cancer worldwide, mainly due to its advanced stage at the time of diagnosis. A non-invasive method for its early detection remains mandatory to improve patients’ survival.

The proteomics platform participated to the validation of a biomarker panel in 48 patients and 49 healthy volunteers. A 6-protein panel clearly distinguished lung cancer from healthy individuals. The panel displayed excellent performance: area under the receiver operating characteristic curve (AUC) = 0.999, positive predictive value (PPV) = 0.992, negative predictive value (NPV) = 0.989, specificity = 0.989 and sensitivity = 0.992. The panel detected lung cancer independently of the disease stage.

This article illustrates targeted mass spectrometry as an emerging antibody-free platform for the validation of protein-based diagnostic assays.

 

https://www.mdpi.com/2072-6694/12/6/1629/htm


Collaboration between:

Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg

Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg

Quantitative Biology Unit, Luxembourg Institute of Health, Strassen Luxembourg

Collaborative Center for Translational Mass Spectrometry, Phoenix, USA

Fred Hutchinson Cancer Research Center, Seattle, USA

Department of Cancer Biology, Mayo Clinic, Scottsdale, USA

Norton Thoracic Institute, Phoenix, USA

Department of cardiac surgery, Luxembourg, Luxembourg

Zithaklinik, Luxembourg , Luxembourg

Department of Biomedicine, University of Bergen, Norway

Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg